Home/Pipeline/ADX71149 (mGlu2 PAM)

ADX71149 (mGlu2 PAM)

Epilepsy

Phase 2Active (with Janssen)

Key Facts

Indication

Epilepsy

Phase

Phase 2

Status

Active (with Janssen)

Company

Addex Therapeutics

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biotech focused on developing a new class of oral drugs—allosteric modulators—for neurological disorders. Its core achievement is building a robust pipeline of eight candidates, with lead programs in Phase 2/3 for Parkinson's disease dyskinesia (dipraglurant) and Phase 2 for epilepsy (ADX71149, partnered with Janssen). The company's strategy centers on advancing its proprietary GPCR modulation platform to create safer, more selective therapeutics, while pursuing strategic partnerships and funding to de-risk development and drive value.

View full company profile

Therapeutic Areas

Neurology Psychiatry

Other Epilepsy Drugs

Drug	Company	Phase	Status
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
NPT 2042	NeuroPro Therapeutics	Phase 2	Active
Spritam (levetiracetam)	Aprecia Pharmaceuticals	Approved	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active
GABA-A PAM for Epilepsy	Modulate Bio	Preclinical	Active